Product Description
Sodium cloxacillin 642-78-4
AI Product Description
*The following content is generated by AI and is for reference only.
Sodium cloxacillin is a semi-synthetic penicillin antibiotic belonging to the isoxazolyl penicillin class, specifically designed to combat bacteria resistant to natural penicillins. Its chemical identity is defined by the molecular formula C19H18ClN3NaO5S and the CAS Registry Number 640-77-3. This sodium salt formulation enhances water solubility, making it suitable for intravenous or intramuscular administration in clinical settings where rapid therapeutic levels are required.
The primary mechanism of action involves the inhibition of bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Unlike ampicillin or amoxicillin, cloxacillin possesses an isoxazole ring that sterically hinders the enzyme beta-lactamase produced by many Staphylococcus species. Consequently, it is highly effective against beta-lactamase-producing strains of methicillin-sensitive Staphylococcus aureus (MSSA) and other coagulase-negative staphylococci. It is not active against methicillin-resistant S. aureus (MRSA), Pseudomonas aeruginosa, or enterococci.
Clinically, Sodium cloxacillin is widely utilized for treating severe infections such as osteomyelitis, septicemia, endocarditis, pneumonia, and skin and soft tissue infections caused by susceptible organisms. It is often administered parenterally due to its poor oral bioavailability compared to its oral counterpart, cloxacillin sodium. The drug demonstrates good distribution into tissues but does not readily cross the blood-brain barrier unless meninges are inflamed. Common side effects include hypersensitivity reactions ranging from mild rashes to life-threatening anaphylaxis, gastrointestinal disturbances, and potential electrolyte imbalances due to its high sodium content. Careful monitoring is essential for patients with renal impairment, as dosage adjustments may be necessary to prevent toxicity. Despite the rise of newer antibiotics, Sodium cloxacillin remains a cornerstone therapy for serious staphylococcal infections where beta-lactamase resistance is a concern, offering a reliable and cost-effective solution in both hospital and community healthcare environments globally.